"
Melatonin: A Powerful Integrative Adjunctive Agent for Oncology"
written by Robert Schettig, Trevor Sears, Matthew Klein, Ruth Tan-Lim, Ronald Matthias, Christopher Aussems, Michael Hummel, Rory Sears, Zachary Poteet, Daniel Warren, John Oertle, Connor Coffin, Dino Prato,
published by
Journal of Cancer Therapy,
Vol.11 No.9, 2020
has been cited by the following article(s):
|
[1]
|
Anti-drug resistance, anti-inflammation, and anti-proliferation activities mediated by melatonin in doxorubicin-resistant hepatocellular carcinoma: in vitro investigations
Naunyn-Schmiedeberg's Archives of Pharmacology,
2023
DOI:10.1007/s00210-023-02385-w
|
|
|
|
|
[2]
|
Melatonin: Regulation of Prion Protein Phase Separation in Cancer Multidrug Resistance
Molecules,
2022
DOI:10.3390/molecules27030705
|
|
|
|
|
[3]
|
The potential anti-cancer effects of melatonin on breast cancer
Exploration of Medicine,
2022
DOI:10.37349/emed.2022.00078
|
|
|
|
|
[4]
|
The promising oncostatic effects of melatonin against ovarian cancer
World Journal of Current Medical and Pharmaceutical Research,
2021
DOI:10.37022/wjcmpr.v3i4.185
|
|
|
|